Trial ID or NCT#



not recruiting iconNOT RECRUITING


The purpose of this study is to determine the safety and efficacy of an investigational therapeutic agent (Cvac) in ovarian cancer patients in first or second remission and to determine its ability to prevent cancer from returning. Study objectives Primary objectives: - To confirm the safety of administering Cvac in this population. - To determine the effects of Cvac on progression-free survival (PFS). Secondary objectives: - To determine overall survival (OS) for ovarian cancer patients who receive Cvac after achieving remission in the first or second-line setting. - Evaluation of host immunologic response to Cvac administration.

Official Title

A Randomized, Open-label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (Cvac™) for Epithelial Ovarian Cancer Patients in First or Second Remission

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: No


Jonathan S. Berek, MD, MMSc
Jonathan S. Berek, MD, MMSc
Gynecologic oncologist
Laurie Kraus Lacob Professor
Nelson Teng

Contact us to find out if this trial is right for you.


Cancer Clinical Trials Office
(650) 498-7061